Last Updated: 24 June 2026
Assort Health has raised $120 million to expand a platform that handles much of the paperwork and phone calls standing between a patient and a doctor. The startup builds AI agents that manage everything from the first phone call to the final payment. It was co-founded by Jon Wang and Jeffery Liu, who now serve as Co-CEOs. Their idea was simple at its core: most of the frustration patients feel in healthcare happens before they ever sit down with a physician, while waiting on hold, filling out a form, or chasing a referral.
That frustration adds up to real money. Administrative spending in the United States costs more than $1 trillion every year. This includes everything from insurance approvals and referral paperwork to the patchwork of software systems that staff have to juggle just to book an appointment or confirm a patient's coverage. Administrative costs still make up nearly 25 to 30 percent of total healthcare spending in the country. That burden has pushed many provider groups to look for automation that can handle more than a single task at once.
The $120 million Series C round was led by Menlo Ventures, valuing the company at $1.2 billion. It brings Assort's total funding to more than $222 million. Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Joe Montana, Tau Ventures, and Quiet Capital also took part. As part of the deal, Menlo Ventures partner JP Sanday is joining Assort's board. Fellow partner Matt Murphy will serve as a board observer.
That administrative burden has drawn a wave of capital aimed at solving it. According to Menlo Ventures' 2025 State of AI in Healthcare report, healthcare organizations are now adopting AI roughly 2.2 times faster than the broader economy. Adoption has climbed from about 3 percent two years ago to a much larger share of the industry today. Menlo Ventures, which led Assort's new round, points to this shift as evidence that healthcare, long seen as slow to modernize, is now adopting AI tools at scale.
Menlo has also been an early backer of Anthropic, the AI company behind the Claude models. The firm's interest in Assort fits into a wider thesis about which kinds of AI companies will matter most as the technology develops further.
"After investing in Anthropic, our thesis was simple: find the best application-layer companies in every category. That is a structural advantage that grows with scale, and it lets Assort deliver outsized value for every customer in a way other platforms simply haven't matched."
Matt Murphy, Partner at Menlo Ventures
The new capital will go toward moving beyond the company's original base of specialty practices and into health system operations. That is a more complicated environment, spanning multiple departments, locations, and patient populations. The expansion is already underway. Health systems such as John Muir Health have adopted the platform to manage increasingly complex outpatient operations. Reaching this part of the market takes deeper integration work, since large health systems typically run on a mix of older software and workflows that differ across departments.
Assort also plans to keep developing Synapse, its AI model built to learn the patterns behind specialty healthcare workflows. The model generates edge cases, tests, and simulations for each new deployment. According to the company, this lets new rollouts go live with high rates of automation, even when the underlying workflows are complicated or differ from one practice to the next.
"This market is going to consolidate in the same way every other one has. Provider groups know it, and the smart ones aren't buying another point solution. They want one partner with the capital and the engineering depth to transform how they operate over the long run."
Jon Wang, Founder and Co-CEO of Assort Health
Assort Health describes its product as an AI agents platform for the patient journey. It is built to handle the work that surrounds a medical visit, not the clinical visit itself. The platform has four connected parts. Concierge handles inbound calls, triage, scheduling, insurance checks, and intake. Activate reaches out to patients to close gaps in care, follow up on missed appointments, and collect payments. Orchestrate manages referrals, document processing, and pre and post visit forms, writing the results back into the patient's electronic health record. Empower gives clinic staff an AI assistant for managing patient access and reviewing performance data.
All four products draw on what the company calls Patient Journey Memory. It is a running record of each patient's interactions across calls, forms, and visits, so an agent handling a billing question already has context from an earlier scheduling or intake conversation. The platform connects to EHR and practice management systems including Epic and Athena, so clinics can use it without replacing their existing clinical software. Assort says its customers see a 5 percent lift in appointment volume, a 115 percent increase in labor capacity, and a patient satisfaction score of 4.3 out of 5. Those numbers are built on more than 190 million patient interactions across more than 62,000 care protocols.
"We evaluated every AI solution on the market. Assort was the only true platform. Everyone else automates one piece and forgets the rest. Assort remembers every patient across every interaction and connects it all into one conversation."
Dr. Parinita Amin, CEO of MDCS Dermatology
Menlo Ventures led this round. The firm has a track record of early bets on companies including Anthropic, Uber, and Roku. It has been particularly active in healthcare AI, publishing research that shows healthcare organizations adopting AI tools faster than most other parts of the economy. Menlo describes application layer healthcare companies, meaning companies that build the software people and patients actually use day to day, as a key part of its investment strategy.
The round also drew Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Tau Ventures, Quiet Capital, and individual investor Joe Montana. Combined with its earlier rounds, Assort has now raised more than $222 million since it was founded.
"Every so often a company comes along that fundamentally reimagines how an industry operates. Assort is that company for healthcare. They've built not just another point solution, but a unified platform of AI agents that elevates the entire patient journey."
JP Sanday, Partner at Menlo Ventures